1. Home
  2. PYPD vs NYXH Comparison

PYPD vs NYXH Comparison

Compare PYPD & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PolyPid Ltd.

PYPD

PolyPid Ltd.

N/A

Current Price

$6.51

Market Cap

107.0M

Sector

Health Care

ML Signal

N/A

Logo Nyxoah SA

NYXH

Nyxoah SA

N/A

Current Price

$0.85

Market Cap

91.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PYPD
NYXH
Founded
2008
2009
Country
Israel
Belgium
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
107.0M
91.6M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
PYPD
NYXH
Price
$6.51
$0.85
Analyst Decision
Strong Buy
Buy
Analyst Count
5
4
Target Price
★ $11.50
$2.80
AVG Volume (30 Days)
193.8K
★ 214.4K
Earning Date
11-11-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$234.49
Revenue Next Year
N/A
$98.07
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.50
$0.80
52 Week High
$7.15
$5.39

Technical Indicators

Market Signals
Indicator
PYPD
NYXH
Relative Strength Index (RSI) 66.10 33.70
Support Level $4.26 $0.80
Resistance Level $7.15 $0.97
Average True Range (ATR) 0.52 0.04
MACD 0.05 0.02
Stochastic Oscillator 62.63 45.97

Price Performance

Historical Comparison
PYPD
NYXH

About PYPD PolyPid Ltd.

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: